Deep Vein Thrombosis Clinical Trial
Official title:
Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture
The research team's aim is to investigate the effects of the team's soft robotic socks in
providing assisted ankle dorsiflexion-plantarflexion and promoting venous blood flow in
stroke patients. Specifically, the investigators intend to 1) observe the development of
joint contracture in terms of the range of motion of the ankle joint given the use of the
device 2) monitor the presence of blood clots in the deep veins using compression Duplex
ultrasonography given the use of the sock device.
The investigators hypothesize that a soft robotics approach can provide compliant actuation
to simulate natural ankle dorsiflexion and plantarflexion, which will consequently promote
blood circulation in the lower leg of stroke patients who have not previously developed ankle
joint contracture. This will prevent the occurrence of DVT and movement in the ankle joint
will alleviate stiffness. This robotic sock intervention is to prevent the development of
ankle joint contracture so established ankle contractures will be excluded from this study.
The investigator's proposed robotic sock solution is capable of providing programmable
robot-assisted ankle exercises to chronic bedridden patients, thereby improving venous blood
flow, and preventing DVT and ankle joint contractures. Compared to conventional mechanical
prophylaxis such as the intermittent pneumatic compression devices, the robotic sock is
likely to cost almost five times less, and potentially generate patient/hospital savings of
up to $2750 per patient. The use of the robotic sock will also raise therapist productivity
through automating the therapy exercises of the bedridden patients, and this could
potentially save the therapists at least 6 workhours per day. The use of the robotic sock in
hospitals, nursing homes and patients' own homes will likely reduce healthcare costs and
prevent side effects, as compared to conventional DVT prophylaxis approaches. In addition, it
will add new values and benefits to public healthcare by eliminating additional treatment
costs arising from DVT-related complications, increasing therapists' productivity (especially
given growing manpower constraints and greying population), optimizing therapy time, and
ultimately saving precious lives.
Among those diagnosed with DVT, 10-30% dies within 1 month of diagnosis (Beckman et al.,
2010), and worldwide 600,000-800,000 people die annually (worldthrombosisday.org). This
research seeks to lower DVT risk through a safe non-drug-based approach by continuously
moving the ankle joint into dorsiflexion-plantarflexion using soft robotics. Current
alternatives to prevent DVT include pharmacological prophylaxis such as anticoagulant drugs,
mechanical prophylaxis such as intermittent pneumatic compression devices and compression
stockings, and the basic therapist-assisted exercises to prevent ankle joint contractures.
Pharmacological prophylaxis can improve venous blood flow and prevent DVT, but run the risk
of detrimental side effects like excessive bleeding. Mechanical prophylaxis can provide
passive or automated stimulation to the calf tissue, but have been reported to deliver
limited efficacy in improving venous blood flow and preventing DVT. Considering the data from
the United States and United Kingdom, the annual spending incurred due to direct and indirect
costs resulting from DVT is approximated to be US$2-10 billion and this ranges from
US$7,594-US$16,644 per patient (Spyropoulos and Lin, 2007). Therefore, by implementing the
robotic sock device, the investigators hope to enable clinicians to focus on treating
patients towards stroke recovery without worrying about other complications.
Joint contractures, usually defined as limited passive range of joint motion are common in
people with neurological conditions such as stroke or spinal cord injury. The risk factors
for joint contractures are not well understood; however, immobility seems to be the most
important factors. Joint contractures, especially in the ankle joints, may impede the ability
to walk and cause loss of balance, high risk of falls and restricted participation in social
activities. The frequency of ankle contractures in hospitalized patients varies with
prevalence rates ranging from 24 % to 44 %.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05003843 -
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
|
N/A | |
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Withdrawn |
NCT04136561 -
Novel Strategy to Encourage Early Removal of Central Venous Catheters
|
N/A | |
Completed |
NCT03420625 -
Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02555111 -
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
|
Phase 3 | |
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Completed |
NCT02037607 -
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT00264277 -
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
|
Phase 4 | |
Completed |
NCT00365950 -
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|
Phase 4 | |
Completed |
NCT00182403 -
Fixed Dose Heparin Study
|
Phase 3 | |
Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
Not yet recruiting |
NCT04981327 -
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT03240120 -
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
|
Phase 3 |